Jefferies analyst Hisae Kawamoto upgraded Rohto Pharmaceutical (RPHCF) to Buy from Hold with a price target of 2,980 yen, up from 2,200 yen. The firm cites the strength of the company’s Asia business for the upgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF: